Eloxx Pharmaceuticals, Inc.
ELOX
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.62M | 9.49M | 10.33M | 11.39M | 12.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.29M | 22.79M | 28.95M | 34.42M | 40.02M |
| Operating Income | -19.29M | -22.79M | -28.95M | -34.42M | -40.02M |
| Income Before Tax | -20.48M | -24.40M | -30.68M | -36.07M | -41.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.48 | -24.40 | -30.68 | -36.07 | -41.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.48M | -24.40M | -30.68M | -36.07M | -41.84M |
| EBIT | -19.29M | -22.79M | -28.95M | -34.42M | -40.02M |
| EBITDA | -19.24M | -22.73M | -28.88M | -34.34M | -39.93M |
| EPS Basic | -9.06 | -11.22 | -14.16 | -16.65 | -19.32 |
| Normalized Basic EPS | -5.60 | -6.90 | -8.73 | -10.41 | -12.07 |
| EPS Diluted | -9.07 | -11.23 | -14.17 | -16.65 | -19.32 |
| Normalized Diluted EPS | -5.60 | -6.90 | -8.73 | -10.41 | -12.07 |
| Average Basic Shares Outstanding | 9.29M | 8.71M | 8.67M | 8.67M | 8.66M |
| Average Diluted Shares Outstanding | 9.29M | 8.71M | 8.67M | 8.67M | 8.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |